Jump to navigation

Mobile menu button
ILD Collaborative logo
  • About
  • Partner Centers
  • People
  • Project ECHO for ILD
    • 2022-2023 Curriculum
      • Idiopathic Pulmonary Fibrosis: A Diagnostic Approach
      • Shifting Paradigms of IPF Pathogenesis
      • Treatments for Idiopathic Pulmonary Fibrosis
      • Overview of Autoimmune ILD
      • Scleroderma-Associated ILD: Clinical Manifestations and Diagnosis
      • Idiopathic Pulmonary Fibrosis: Natural History and Survival
      • Myositis-Associated ILD: Clinical Manifestations and Diagnosis
      • Lung Biopsy in the Diagnosis of Fibrotic ILD
      • Sarcoidosis: Overview, Diagnosis and Monitoring
      • Rethinking Classification Criteria for Connective Tissue Diseases
      • Post-acute Sequelae of COVID-19 (PASC)
      • Acute Exacerbations of ILD
      • Scleroderma-Associated ILD: Treatment Approaches and Challenges
      • Myositis-Associated ILD: Treatment Approaches and Challenges
      • Pulmonary Hypertension Associated with ILD
      • More Than Meds: Nonpharmacologic Treatments for ILD
      • Hypersensitivity Pneumonitis: Approach and Challenges
      • Lung Transplant for ILD: When to Refer and What to Expect
      • Sarcoidosis: Beyond First Line Therapy
      • Genetics and the Development of Pulmonary Fibrosis
      • Hypersensitivity Pneumonitis: Treatment Approach and Challenges
      • HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
      • Common Comorbidities of ILD
      • Quality of Life and ILD: Palliative Care Along the Trajectory of Illness
    • 2024-2025 Curriculum
      • Rheumatoid Arthritis-Associated ILD
      • Shifting Paradigms of IPF Pathogenesis
      • HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
      • Myositis-Associated ILD: Clinical Manifestations and Diagnosis
      • Emerging Treatments for Pulmonary Fibrosis and Active Clinical Trials
      • Lung Cancer in Patients with ILD: Diagnostic and Management Considerations
      • Rethinking Classification Criteria for Connective Tissue Diseases
      • A Guide to Immunosuppression
      • Lung Biopsy in the Diagnosis of ILD
      • Hypersensitivity Pneumonitis: Diagnostic Approach and Challenges
      • ANCA-associated ILD
      • Acute Exacerbations of ILD
      • Scleroderma-Associated ILD: Treatment Approaches and Challenges
      • Pulmonary Complications of Immunotherapy
      • Post-acute Sequelae of COVID-19 (PASC): “Long-haulers” and Pulmonary Disease
      • Hypersensitivity Pneumonitis: Update on Treatment Approaches
      • Pulmonary Hypertension Associated with ILD: Diagnosis and Management
      • Occupational Lung Disease
      • Myositis-Associated ILD: Treatment Approaches and Challenges
      • Lung Transplant for ILD: When to Refer and What to Expect
      • Obliterative Bronchiolitis
      • Sarcoidosis: Conventional and Evolving Treatments
      • Quality of Life and ILD: The Role of Palliative Care
      • Genetics and the Development of Pulmonary Fibrosis
      • Common Comorbidities of ILD
    • Project ECHO for ILD
    • Registration
      • Unsubscribe from Project ECHO for ILD
  • Virtual Meetings
    • Air Filtration
    • Air Pollution and Interstitial Lung Disease
    • Airway Clearance
    • Anesthesia for People With Interstitial Lung Disease
    • Art Therapy in Chronic Illness
    • Cough in ILD: Its Causes and Management
    • Eight Active Ingredients of Tai Chi
    • Gastroesophageal Reflux Disease (GERD) and ILD
    • Hypersensitivity Pneumonitis
    • Immunomodulatory Agents in the Treatment of ILD
    • Implementing Energy Conservation Strategies
    • Interstitial Lung Disease: The Journey to Diagnosis and Treatment
    • Living Better with ILD
    • Lung Transplant: Eligibility and Evaluation
    • Monthly Oxygen Therapy Series: Is It Time to Use Oxygen?
    • Monthly Oxygen Therapy Series: Portable Oxygen Concentrators and Travel
    • Monthly Palliative Care Series: Palliative Care and QoL in ILD
    • Nutritional Considerations for ILD
    • Pranayama: The Art and Science of Slow Breathing
    • Pulmonary Hypertension: Diagnosis and Management
    • Sarcoidosis: Is There Better Treatment?
    • The Lived Experience Series: Financial and Tax Planning
    • The Role of Ablation for Lung Cancer Treatment in ILD
    • Understanding Autoimmune-Related ILD
    • Unsubscribe from our Mailing Lists
    • Updates on Clinical Research for IPF and Other Forms of ILD (2023)
    • Updates on Clinical Research for IPF and Other Forms of ILD
  • Resources
    • Aspirational Patient Journey
      • Aspirational Patient Journey
    • Basics of ILDs
    • Basics of IPF
    • Blog
    • Genetics of Familial Idiopathic Interstitial Pneumonia
    • IPF Patient Journey
      • Early Symptoms
      • Delayed Diagnosis
      • IPF Diagnosis
      • Pharmacologic Treatments
      • Making Sense of the Illness
      • Oxygen Therapy
      • Pulmonary Rehabilitation
      • Acute Exacerbations
      • Lifestyle Changes
      • Palliative Care
      • Hospice Care
      • Lung Transplant
    • IPF and PF-ILD Clinical Trials
    • Monitoring Disease Progression in Idiopathic Pulmonary Fibrosis
    • Patient Symposium
    • Peer To Peer Support
    • Phase IV IPF Clinical Trials
    • Pulmonary Function Testing
    • Starting Oxygen Therapy
    • Support Groups
    • Webinars
  • Clinical Trials
    • PCRC Patient Registry
    • BMS-986278-IPF
    • BMS-986278-PPF
    • Bexotegrast-IPF
    • DWN12088-IPF
    • EFZO-FIT
    • FIBRONEER-IPF
    • FIBRONEER-PF-ILD
    • Inhaled Treprostinil Clinical Trial
    • PRECISIONS Trial
  • Home
  • Contact
  • Support
  • Events
  • Tai Chi
  • ILD Centers in the USA
  • Pulmonary Rehab Programs
  • Search
  • Login

You are here

  1. Home ›
  2. Resources ›

Questions & Answers

If you would like to submit a questions please visit this page.

Question
How do the lungs work?
Why am I getting chest pain?
What is pulmonary arterial hypertension, and is it a problem of my heart or lungs?
What are the causes of chest pain that are more specific to pulmonary arterial hypertension?
Would a change in diet help with my pulmonary arterial hypertension?
What is inflammation, and what is scarring/fibrosis, and what tissue in the lung is affected by either or both in ILDs?
What are the differences between Idiopathic Pulmonary Fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)?
What is the role of steroids in the treatment or management of interstitial lung diseases?
What are the genetic risks of developing IPF or other forms of idiopathic interstitial lung diseases?
When is it recommended that a patient be evaluated for a lung transplant?
  • Home
  • Contact
  • Support
  • Events
  • Tai Chi
  • ILD Centers in the USA
  • Pulmonary Rehab Programs
  • Search
  • Login
  • About
  • Partner Centers
  • People
  • Project ECHO for ILD
  • Virtual Meetings
  • Resources
  • Clinical Trials

SUBSCRIBE TO OUR MAILING LISTS

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Copyright © 2024 Pulmonary Care and Research Collaborative, Ltd. 
Privacy Policy | Terms of Use



  • Kazançlı bir başlangıç yapmak için deneme bonusu sunan bu siteye göz atabilirsiniz.
  • Fırsatlarla dolu deneme bonusu veren siteler arasında öne çıkan bir seçenek burada.
  • Yeni üyeler için özel bonus veren siteler, avantajlı teklifleriyle dikkat çekiyor.
  • Kullanıcı memnuniyetine odaklanan bonus veren siteler, eşsiz fırsatlar sunuyor.
  • Güvenilir bir deneyim için deneme bonusu veren siteler, kazanç kapınızı aralıyor.
  • Hızlı kazanç fırsatı sağlayan deneme bonusu seçeneklerini keşfedin.
  • Avantajlı teklifleriyle deneme bonusu veren siteler, yüksek kazanç imkanı sunuyor.